Pfiz­er and Val­ne­va say sec­ond Ly­me boost­er led to 'strong' re­spons­es, tar­get 2026 FDA sub­mis­sion

Pfiz­er and Val­ne­va said pa­tients demon­strat­ed “strong im­mune re­spons­es” af­ter re­ceiv­ing a sec­ond boost­er dose of their ex­per­i­men­tal Ly­me dis­ease vac­cine, sup­port­ing the case for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER